Roche to Buy Telavant from Roivant Sciences and Pfizer in $7.25B Deal

Roche Holding has agreed to buy Telavant Holdings from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion that will give it rights to a therapy for inflammatory bowel disease and potentially multiple other indications. The Swiss pharmaceutical giant said Monday that it will pay $7.1 billion upfront and make a near-term milestone payment of $150 million to acquire rights to develop and manufacture Telavant’s RVT-3101 drug candidate and commercialize it in the U.S. and in Japan. Telavant was jointly formed by Roivant and Pfizer last year to develop and commercialize RVT-3101 in the U.S. and Japan, with Roivant owning a 75% stake and Pfizer holding the remaining 25%, Roche said.

Read the full article: Roche to Buy Telavant from Roivant Sciences and Pfizer in $7.25B Deal //

Source: https://www.wsj.com/health/pharma/roche-to-buy-telavant-from-roivant-sciences-and-pfizer-in-7-25-bln-deal-638ccc3c

Leave a Comment

Your email address will not be published.

Scroll to Top